Loaded With Gimmicks, but Still Worth It
The debt-limit deal is disappointing, but Congress cannot risk economic calamity.
Beware the Hype Over Two New Alzheimer’s Drugs
They could cost taxpayers billions while potentially delivering few benefits.
Get Ready for More ‘Bud Lighting’
The beermaker is suffering a sales slump, but boycotters don’t even need to hurt a company’s bottom line to declare victory.